echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > "Double Resistance" trend! AbbVie, Sanofi and many other MCCs spend a lot of money plus code layout

    "Double Resistance" trend! AbbVie, Sanofi and many other MCCs spend a lot of money plus code layout

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Encountered the epidemic of the stage disturbance, the pharmaceutical industry's investment transactions experienced a short period of ambush, into the post-epidemic era, the crisis, the major enterprises have to their own optimistic projects throw an olive branchNotably, this week Roche, Sanofi and AbbVie have all set their sights on the field - BsAbBispecific antibodies are artificial antibodies containing two specific antigen binding sites that can interact with both target cells and functional cells (generally T cells) to mediate a series of immune responsesCompared to monophox, bispecific antibodies add a specific antigen binding site, so the advantages in treatment are also significantAt the end of May, Science reported a story about BsAb's healingThe woman, Amy Boland, had battled lymphoma for years and had been treated with CAR-T, but had a recurrence, eventually disappearing after receiving bispecific antibody treatment, and has not yet relapsedThe huge therapeutic potential has made bispecific antibodies the "new darling" of new drug research and development investmentStrong joint trading bispecific antibodies do not exist in the natural state, need to be achieved through the recombined DNA or cell fusion technology artificial preparation, research and development is relatively difficult, so it is wise to choose a partner in the research and development processSeveral deals involving BsAb were reached this weekOn June 11, AbbVie and Genmab jointly announced that they had reached a broad cooperation agreement to jointly develop and commercialize three new generation bispecific antibody products under GenmabUnder the agreement, AbbVie will make a down payment of $750 million to Genmab and a total of $3.15 billion in development, registration and sales milestone paymentsOn June 9, Cinda Bio announced a strategic development partnership with Roche, which will focus on research, clinical development and commercialization of multiple bispecific antibody and cell therapy productsCinda will use Roche's technology platform to develop, produce and commercialize its productsRoche reserves the exclusive repurchase option for the development and commercialization of these products outside ChinaIf Roche exercises all of its options, it will make a down payment of $140 million to Cinda and a milestone payment totalling about $1.96 billionOn the same day, Sanofi and Corning-Jerry announced that they had signed an agreement on strategic cooperation: the two sides will jointly promote clinical trials of bispecific antibody KN026 and Docetaxel in combination with dosage for HER2-positive breast cancer patientsAfter reaching a specific clinical milestone, Sanofi will have the right to negotiate an exclusive right to introduce KN026 within the exclusive periodTwo more months before, on April 9, Reding Pharmaceuticals and Regenerative Yuan reached a strategic cooperation on the development and commercialization of CD20xCD3 dual-specific antibody REGN1979 in Chinese mainland, Hong Kong, Taiwan and Macau, and on March 24, CytomX Therapeutics and Astellas reached a strategic partnership worth approximately US$1.7 billion to jointly discover, develop and commercialize new T-cell dual-specific antibodiesThis article lists only a small part of the many related transactions, but to some extent reflects the investment fever of dual-characteristic antibodiesThe world's first dual-characteristic antibodies are also ready to start again at a time when the candidate bi-characteristic antibody trade is in full swingOn June 4, the CDE website showed that the world's first dual-specific antibody catumaxomab injection (Katoso monobize injection) was approved in China for two clinical trials, indicating that the indications were "not suitable for general treatment and treatment of advanced gastric cancer with peritoneal metastasis"Catumaxomab was approved by the European EMA in 2009 for the treatment of malignant ascites, but underperformed after the market, which resulted in the de-listing and discontinuation in 2017Promising pipeline outbreaks of bispecific antibodies are developed on the basis of monotophos, and the therapeutic effect may be better, is regarded as the second generation of antibody therapy for tumor therapy, so its market prospects can be predicted from the sale of monotophosThe global singopharmaceutical market grew from $88.3 billion in 2014 to $144.8 billion in 2018, with a COMPOUND growth rate of 13.2%, well above the global compound growth rate of 7.7%In addition, monotohak seditu at the top 20 drugs in global sales in 2019Only three bispecific antibody drugs have been approved for sale worldwideIn addition to the catumaxomab mentioned above, the other two are Amin's Blincyto and Roche's HemlibraTable 1 The global approved bispecific antibody drug Catumaxomab has been re-launched and has locked in the large-scale indication of stomach cancer, and the determination to return strongly is self-evidentSo how are the two bispecific antibody drugs on sale? In 2019, Blincyto's sales of $312 million have been approved in ChinaSince its launch in 2017, Hemlibra's sales have grown rapidly, reaching CHF 1.38 billion in 2019, up 516 percent year-on-yearWhile Blincyto and Hemlibra are "getting better" and, in particular, Hemlibra's performance is a bit of a point, this is only the tip of the iceberg for the entire bispecific antibody market, with a wider space waiting to be opened upIn recent years, the research and development pipeline of bispecific antibodies has seen a major outbreakLast year, Nature Reviews Drug Discovery published a review of bispecific antibodies, which showed that since 2014, bispecific antibodies have entered a period of rapid development As of March 2019, there were 85 bispecific antibodies in clinical development There are certainly more than 100 bispecific antibody drugs in the world at the clinical stage Figure 1 2010-2018 Bispecific Antibody Clinical Research Start Source: Nature Reviews Drug Discovery, according to statistics, about 20% of the world's antibody drugs in the preclinical stage are bispecific antibodies, and the proportion in China is slightly higher, about 22% Wait for guacamole is another competition, and then we interpret the situation in the study of bispecific antibodies from different angles In the field of disease, the main research focus on bispecific antibodies worldwide remains in tumors (86%) (as of March 2019), followed by blood diseases and autoimmune diseases China's dual-specific antibody program is almost entirely targeted at tumors, and breast and stomach cancers are mostly concentrated Figure 2 Bispecific Antibody Clinical Pipeline Source: Nature Reviews Drug Discovery From a Target Perspective, the Global Bispecific Antibody Project is concentrated in PD-1/PD-L1, HER2, CTLA4, CD19, BCMA Chinese companies layout HER2 the most From the enterprise point of view, according to the pharmaceutical Rubik's Cube global database of new drugs NextPharma, in the number of projects and development progress in the first echelon, foreign countries are mainly Anjin, Roche, Genmab, MacroGenics, Xencor, Johnson and Johnson, AstraZeneca, regenerative yuan, etc , the domestic main lying Jerry, Baiji Shenzhou, Shore-Mai Biological, Cinda Biology and so on Figure 3 At home and abroad bispecific antibodies on behalf of the enterprise source: Pharmaceutical Rubik's Cube from the development of progress, the global research of bispecific antibody drugs also nearly 80% in the clinical stage of Phase I The fastest-growing in the world is AstraZeneca and Regeneration, each with one project in the clinical phase III The fastest-growing countries in The Country are Corning Jerry and Baiji Shenzhou, with two and one project in clinical phase TWO, respectively While they all hope to enjoy the first-mover advantage and lay out the market early, most of the products in the research are in the early stages and are concentrated in the direction of the tumor, thus foreseeing the future of the global bispecific antibody market fierce competition.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.